David John Werring FRCP (born October 1967) is a British physician, neurologist, and academic specialising in stroke. He is professor of Neurology at the UCL Queen Square Institute of Neurology and current head of Stroke Research Centre and the department of Brain Repair & Rehabilitation at UCL.
David J Werring | |
|---|---|
| Nationality | British |
| Education | Guy’s Hospital Medical School, King's College London |
| Alma mater | University College London |
| Occupation(s) | Neurologist, Clinical researcher, Stroke physician |
| Medical career | |
| Institutions | |
| Sub-specialties | Neurology |
| Research | Stroke |
Career edit
Werring received his Bachelor in Neurosciences in 1989 and his Bachelor in Medicine/Bachelor in Surgery from Guy's Hospital Medical School in 1992. He became a Member of the Royal Colleges of Physicians of the United Kingdom (MRCP) in 1995 and finished his PhD in clinical neurology at the UCL Queen Square Institute of Neurology in 2000.[1] After completing his clinical training in neurology and stroke medicine in 2004, he was appointed consultant neurologist at the National Hospital for Neurology and Neurosurgery, University College Hospital and Watford General Hospital in 2005.[2] Werring was made Reader in clinical neurology and honorary consultant neurologist in 2008, became a fellow of the Royal College of Physicians (FRCP) in 2012 and was made full professor at UCL Queen Square Institute of Neurology in 2015. In 2017, he became head of the research department of Brain Repair & Rehabilitation at the UCL Queen Square Institute of Neurology.[2]
Werring is a recognized expert in the field of stroke, chaired the UK Stroke Forum 2020-2022 and is President of the British and Irish Association of Stroke Physicians since December 2023.[3][4]
Scientific expertise edit
The core field of research of Werring is stroke, in particular cerebral small vessel disease, intracerebral hemorrhage and cerebral amyloid angiopathy.[2] He has published more than 400 peer-reviewed articles on those topics and in other fields of clinical neurology.[2] Werring has led large collaborative studies investigating cerebral microbleeds and has expertise in neuroimaging, with a focus on brain MRI.[1] He is currently the primary investigator of a large multi-centre study investigating the timing of oral anticoagulation after ischemic stroke, founded by the British Heart Foundation[5] and has been involved in several studies investigating the influence of COVID-19 and respective vaccines on stroke.[6] He has an h-index of 97,[7] and is an editor of the Queen Square textbook of Neurology and editorial board member of several scientific journals, including the European Stroke Journal, International Journal of Stroke, Practical Neurology, and the European Journal of Neurology.[8][9][10]
Selected works edit
- Best, JG; Ambler, G; Wilson, D; et, al; Werring, DJ (2021). "Microbleeds International Collaborative Network. Development of imaging-based risk scores for prediction of intracranial haemorrhage and ischaemic stroke in patients taking antithrombotic therapy after ischaemic stroke or transient ischaemic attack: a pooled analysis of individual patient data from cohort studies". The Lancet Neurology. 20 (4): 294–303. doi:10.1016/S1474-4422(21)00024-7. hdl:20.500.11820/2a6b028d-ef79-48f6-89f3-99640f99e935. PMID 33743239. S2CID 232265303.
- Seiffge, DJ; Werring, DJ; Paciaroni, M; Dawson, J; Warach, S; Milling, TJ; Engelter, ST; Fischer, U; Norrving, B (2019). "Timing of anticoagulation after recent ischaemic stroke in patients with atrial fibrillation". The Lancet Neurology. 18 (1): 117–126. doi:10.1016/S1474-4422(18)30356-9. PMC 6524642. PMID 30415934.
- Wilson, D; Ambler, G; Lee, K-J; et, al; Werring, DJ (2019). "Cerebral microbleeds and stroke risk after ischaemic stroke or transient ischaemic attack: a pooled analysis of individual patient data from cohort studies". The Lancet Neurology. 18 (7): 653–665. doi:10.1016/S1474-4422(19)30197-8. PMC 6562236. PMID 31130428.
- Wilson, D; Ambler, G; Shakeshaft, C; et, al; Werring, DJ (2018). "CROMIS-2 collaborators. Cerebral microbleeds and intracranial haemorrhage risk in patients anticoagulated for atrial fibrillation after acute ischaemic stroke or transient ischaemic attack (CROMIS-2): multicentre observational cohort study". The Lancet Neurology. 17 (6): 539–547. doi:10.1016/S1474-4422(18)30145-5. PMC 5956310. PMID 29778365.
- Banerjee, G; Carare, R; Cordonnier, C; Greenberg, SM; Schneider, JA; Smith, EE; Buchem, MV; Grond, JV; Verbeek, MM; Werring, DJ (2017). "The increasing impact of cerebral amyloid angiopathy: essential new insights for clinical practice". Journal of Neurology, Neurosurgery, and Psychiatry. 88 (11): 982–994. doi:10.1136/jnnp-2016-314697. PMC 5740546. PMID 28844070.
References edit
- ^ a b "Iris View Profile". iris.ucl.ac.uk. Retrieved 2022-12-20.
- ^ a b c d "Professor David Werring". University College London Hospitals NHS Foundation Trust. Retrieved 2022-12-20.
- ^ "Committees". BIASP - The British Irish Association of Stroke Physicians. Retrieved 2 Jan 2023.
- ^ Werring, D (25 Oct 2021). "The UK Stroke Forum: a vital opportunity for collaboration in a virtual world". British Journal of Neuroscience Nursing. 17: S6. doi:10.12968/bjnn.2021.17.Sup5.S6. S2CID 239989379.
- ^ British Heart Foundation. "New trial could prevent further strokes and reduce hospital time". British Heart Foundation. Retrieved 2 January 2023.
- ^ "Covid-19 vaccine: Common stroke symptoms must be 'urgently evaluated'". University College London Hospitals NHS Foundation Trust. Retrieved 2023-01-02.
- ^ "David Werring". scholar.google.co.uk. Retrieved 2023-01-02.
- ^ World Stroke Organization. "Editorial board". International Journal of Stroke. Retrieved 2 Jan 2023.
- ^ European Journal of Neurology. "Editorial Board". European Journal of Neurology. Retrieved 2 Jan 2023.
- ^ European Stroke Organisation. "Editorial Board". European Stroke Journal. Retrieved 2 Jan 2023.